靶向树突状细胞的慢病毒载体乳腺癌疫苗诱导强效抗肿瘤免疫反应并保护小鼠免于乳腺肿瘤生长
该研究将慢病毒载体疫苗伪型化以靶向树突状细胞,递送乳腺癌抗原α-乳白蛋白或ERBB2/HER2基因。单次注射使抗原特异性CD8T细胞较 naïve 小鼠扩增4-6倍,在外源抗原环境中完全抑制肿瘤生长,在自身抗原环境中降低肿瘤生长速率。结果表明单次注射靶向慢病毒载体可作为乳腺癌的有效免疫治疗,并可能与其他免疫治疗方案联合。
要点
- 单次注射靶向树突状细胞的慢病毒载体疫苗使抗原特异性CD8T细胞较 naïve 小鼠扩增4-6倍。
- LV-ERBB2在野生型小鼠(外源抗原环境)中完全抑制肿瘤生长。
- LV-Lalba在野生型或LV-ERBB2在MMTV-huHER2转基因小鼠(自身抗原环境)中降低肿瘤生长速率。
核心结论
- 单次注射靶向慢病毒载体可作为乳腺癌的有效免疫治疗,并可能与其他免疫治疗方案联合以改善乳腺癌患者结局。
研究设计与样本
- 研究将慢病毒载体疫苗用修饰的辛德毕斯病毒糖蛋白伪型化以靶向树突状细胞,递送编码乳腺癌抗原α-乳白蛋白(Lalba)或erb-b2受体酪氨酸激酶2(ERBB2或HER2)的基因。
主要发现
- 单次注射疫苗载体使抗原特异性CD8T细胞较 naïve 小鼠扩增4-6倍,与已发表的最佳疫苗方案相似。
- LV-ERBB2在野生型小鼠(外源抗原环境)中完全抑制肿瘤生长。
- LV-Lalba在野生型小鼠或LV-ERBB2在MMTV-huHER2转基因小鼠(自身抗原环境)中降低肿瘤生长速率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast cancer immunotherapy is a potent treatment option, with antibody therapies such as trastuzumab increasing 2-year survival rates by 50%. However, active immunotherapy through vaccination has generally been clinically ineffective. One potential means of improving vaccine therapy is by delivering breast cancer antigens to dendritic cells (DCs) for enhanced antigen presentation. To accomplish this in vivo, we pseudotyped lentiviral vector (LV) vaccines with a modified Sindbis Virus glycoprotein so that they could deliver genes encoding the breast cancer antigen alpha-lactalbumin (Lalba) or erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2) directly to resident DCs. We hypothesized that utilizing these DC-targeting lentiviral vectors asa breast cancer vaccine could lead to an improved immune response against self-antigens found in breast cancer tumors. Indeed, single injections of the vaccine vectors were able to amplify antigen-specific CD8T cells 4-6-fold over naïve mice, similar to the best published vaccine regimens. Immunization of these mice completely inhibited tumor growth in a foreign antigen environment (LV-ERBB2 in wildtype mice), and it reduced the rate of tumor growth in a self-antigen environment (LV-Lalba in wildtype or LV-ERBB2 in MMTV-huHER2 transgenic). These results show that a single injection with targeted lentiviral vectors can be an effective immunotherapy for breast cancer. Furthermore, they could be combined with other immunotherapeutic regimens to improve outcomes for patients with breast cancer.
引用
- Bryson PD, Han X, Truong N, et al. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth. Vaccine. 2017. PMID: 28916248. doi:10.1016/j.vaccine.2017.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。